Press release with respect to financial results of H1FY26
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported strong H1FY26 results with consolidated revenue of INR 280.7 crore, up 57% YoY, and EBITDA of INR 69.1 crore, up 173% YoY. Profit after tax jumped 664% YoY to INR 39.6 crore, with diluted EPS of INR 13.87. Q2FY26 revenue rose 39% YoY to INR 135.7 crore, though down 6% QoQ. The Vitamin D3 human nutrition segment led growth at +80% YoY (INR 158.8 crore), while Environmental Solutions surged 127%. The German subsidiary revenue nearly tripled (+194%) to INR 34.3 crore. The company also received a patent for its plant-based Vitamin D3 process and transferred its Environment Division to a wholly-owned subsidiary for INR 19 crore.
Strong double-digit revenue and triple-digit profit growth signal a continued turnaround, likely positive for shareholder sentiment and stock price. The patent grant and segment restructuring could unlock further value, though some growth was aided by a non-recurring insurance claim of INR 2.7 crore.